Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes

Journal of Thrombosis and Thrombolysis

Volumn 18, Issue 3, 2004, Pages 171-175

  Mascelli, Mary Ann ^a   Deliargyris, Efthymios N ^b   Damaraju, Lakshmi V ^a   Barnathan, Elliot S ^a,b   Califf, Robert M ^c   Simoons, Maarten L ^d   Sane, David C ^b  

^a CENTOCOR INC   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Thoraxcenter Erasmus Medical Center   (Netherlands)

Author keywords

Antibodies; Heparin; Inflammation; Myocardial infarction; Platelets

Indexed keywords

ABCIXIMAB; C REACTIVE PROTEIN; CELL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PADGEM PROTEIN; PLACEBO; THROMBOCYTE FACTOR 4; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CELL ACTIVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EXPOSURE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; THROMBOCYTOPENIA;

EID: 17544382502     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-0342-9     Document Type: Article

References (20)

1. Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/ heparin antibodies. An Independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 2003;107:2307-2312.
2. Ross R. Mechanisms of disease: Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-126. 10.1056/NEJM199901143400207
3. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003;41:37S-42S.
4. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-1292.
5. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41. 1:STN:280:CSmD2srptFU%3D
6. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
7. Hosono M, de Boer OJ, van der Wal AC, et al. Increased expression of T cell activation markers (CD25, CD26, CD40L and CD69) in atherectomy specimens of patients with unstable angina and acute myocardial infarction. Athersclerosis 2003;168:73-80.
8. Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000;102:2883-2888.
9. Shaw PX, Hörkkö S, Chang M-K, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Inves 2000;105:1731-1740.
10. MHF Klinger 2002 Inflammation in Platelets, Michelson AD ed. Platelets Academic Press Amsterdam 459-467
11. Schumacher A, Seljeflot I, Lerkerod AB, Sommervoll L, Otterstad JE, Arnesen H. Does infection with Chlamydia pneumoniae and/or Helicobacter pylori increase the expression of endothelial cell adhesion molecules in humans? Clin Microbiol Infect 2002;8:654-661.
12. Mrowka C, Sieberth HG. Detection of circulating adhesion molecules ICAM-1, VCAM-1 and E-selectin in Wegener's granulomatosis, systemic lupus erythematosis and chronic renal failure. Clin Nephrol 1995;43:288-296.
13. Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol 1996;81:96-98.
14. Lieuw-A-Fa M, Schalkwijk C, Van Hinsbergh VW. Distinct accumulation patterns of soluble forms of E-selectin, VCAM-1 and ICAM-1 upon infucion of TNFalpha in tumor patients. Thromb Haemostas 2003;89:1052-1057
15. Blann AD, Lip GY, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: A comparison with endothelial cell and platelet markers. Thomb Haemost 1997;77:1077-1080.
16. Herbert J-M, Savi P, Jeske WP, Walenga JM. Effect of SR121566A, a potent GP IIb/IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Throm Haemost 1998;80:326-331.
17. Blank M, Shoenfeld Y, Tavor S, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. International Immunology 2002;14:121-129.
18. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-589.
19. James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: A GUSTO-IV substudy. JACC 2003;41:916-924.
20. Ridker PM. Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention. Circulation 2003;107:363-369.